Ghesquieres, H., Krawczyk-Kulis, M., Chraniuk, D., Kwiatek, M., Nogai, H., Saba, C., Falkowski, A., Kucharz, K., Kulesza, M., Curley, R., Wilkinson, G., Juszczynski, P., Bertoni, F., Bellarosa, D., Galleu, A., Gupta, I., Dlugosz-Danecka, M., Jurczak, W., Cartron, G., Nowakowski, G. (2025). An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2025-5481